The aldo‐keto reductase (AKR) Kd AKR from Kluyvermyces dobzhanskii can reduce t ‐butyl 6‐chloro‐(5 S )‐hydroxy‐3‐oxohexanoate ((5 S )‐CHOH) to t ‐butyl 6‐chloro‐(3 R ,5 S )‐dihydroxyhexanoate ((3 R ,5 S )‐CDHH), which is the key chiral intermediate of rosuvastatin. Herein, a computer‐aided design that combined the use of PROSS platform and consensus design was employed to improve the stability of a previously constructed mutant Kd AKR M6 . Experimental verification revealed that S196C, T232A, V264I and V45L produced improved thermostability and activity. The “best” mutant Kd AKR M10 ( Kd AKR M6 ‐S196C/T232A/V264I/V45L) was constructed by combining the four beneficial mutations, which displayed enhanced thermostability. Its T 50 15 and T m values were increased by 10.2 and 10.0°C, respectively, and half‐life ( t 1/2 ) at 40°C was increased by 17.6 h. Additionally, Kd AKR M10 demonstrated improved resistance to organic solvents compared to that of Kd AKR M6 . Structural analysis revealed that the increased number of hydrogen bonds and stabilized hydrophobic core contributed to the rigidity of Kd AKR M10 , thus improving its stability. The results validated the feasibility of the computer‐aided design strategy in improving the stability of AKRs.
No takes yet. Share an insight, caveat, or question.
Dai et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: